Lineage Announces Appointment of Dr. Dipti Amin to Its Board of Directors

Rhea-AI Summary

Lineage Cell Therapeutics (NYSE American: LCTX) has appointed Dr. Dipti Amin to its Board of Directors as of April 20, 2021. Dr. Amin, a seasoned Non-Executive Director with over 26 years in the pharmaceutical sector, brings extensive experience in clinical research, drug development, and compliance. The company’s Chairman, Al Kingsley, emphasized her ability to significantly advance Lineage’s mission to lead in allogeneic cell transplants. Dr. Amin expressed her enthusiasm about contributing to the company’s growth and guiding its product candidates towards later-stage clinical trials.

Positive

• Dr. Amin's extensive experience in clinical research and drug development may strengthen Lineage's strategic positioning.
• Her expertise is anticipated to enhance the company's guidance in advancing cell therapy product candidates.

Negative

• None.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell transplants for serious medical conditions, today announced the appointment of Dr. Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM, to the Company’s Board of Directors, effective as of April 20, 2021. Dr. Amin is an experienced Non-Executive Director and a medically trained senior executive with broad expertise in medicine, pharmacology, healthcare, research, and product development. Dr. Amin has more than 26 years of experience within the pharmaceutical sector and is accomplished across diverse functional areas including clinical research, drug development, ethics and compliance, and commercial operations. She currently serves as a Non-Executive Director on the board of directors of Buckinghamshire Healthcare National Health Service Trust and the University of Hertfordshire in the UK.

“We are honored that Dr. Amin will be joining Lineage’s Board of Directors at this important time in the advancement of our mission to become the leading allogeneic cell transplant company,” stated Al Kingsley, Lineage’s Chairman of the Board. “Dr. Amin has had leadership responsibility for many aspects of pharmaceutical product development and clinical trials and has worked with numerous sponsors on countless product candidates while at Quintiles (now IQVIA). We believe her breadth of experience in clinical research and drug development, as well as her medical expertise and practical operational experience, will be particularly valuable to our Board and management team as Lineage continues to advance its three product candidates toward later stage clinical trials. We look forward to her support in guiding our corporate, product, and clinical strategy as we position ourselves for years of growth in the field of cell therapy.”

“Lineage’s clinical-stage programs and platform technologies have the potential to transform outcomes for patients suffering from serious medical conditions,” stated Dr. Amin. “I am excited about the opportunity to contribute to the Company’s future growth. I particularly look forward to helping guide the advancement of Lineage’s novel cell therapy product candidates toward later-stage clinical trials and the execution of other potentially valuable development activities, with an ultimate focus on transforming the lives of patients and creating value for the Company’s shareholders.”

Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM

Dipti Amin is an experienced Non-Executive Director and medically trained senior executive with a passion for high quality pharmaceutical research and healthcare, and extensive commercial, leadership, operational experience, in the private & public sectors, in medicine, pharmacology and the highly-regulated healthcare & research sectors, as well as compliance expertise. Over a span of more than 26 years, Dr. Amin has held positions of operational and strategic responsibility within Pharmaceutical Services at the C-suite and Board level, delivering consistently on growth, quality, customer, employee and process targets. Her broad experience covers Clinical Pharmacology, ethical issues in clinical research, drug development, ethics and compliance programs as well as leadership and management of large, multi-functional, multi-geography, global groups to deliver value-added, efficient growth and achieving business turnarounds. Dr. Amin has extensive international operational experience, including in the U.S., India, East Asia and Africa.

Dr. Amin spent more than 20 years at Quintiles Transnational (now IQVIA), the world’s largest provider of biopharmaceutical development & commercial outsourcing services. During her tenure, Dr. Amin served in a number of senior executive roles including: Compliance; Ethics & Quality; Drug Safety and Medical Affairs; Medical and Scientific Services; Regulatory Affairs, Medical Writing and Strategic Drug Development; and Clinical Development and Scientific Operations. Dr. Amin has successfully developed strategy and helped grow the P&L, sales & management for business un

FAQ

Who is Dr. Dipti Amin and what is her role at Lineage Cell Therapeutics?

Dr. Dipti Amin is a highly experienced Non-Executive Director appointed to the Board of Lineage Cell Therapeutics, effective April 20, 2021.

What experience does Dr. Dipti Amin bring to Lineage Cell Therapeutics?

Dr. Amin has over 26 years of experience in the pharmaceutical sector, specializing in clinical research, drug development, and compliance.

What impact could Dr. Amin's appointment have on Lineage Cell Therapeutics?

Her appointment could provide valuable insights and leadership as Lineage advances its product candidates towards later-stage clinical trials.

When was Dr. Amin appointed to the Board of Lineage Cell Therapeutics?

Dr. Amin was appointed to the Board on April 20, 2021.